In light of the possible, significant superiority of Altimmune, Inc.'s (NASDAQ: ALT ) weight loss drug in multiple, important areas, the company is likely to become a takeover target in the medium-to-long term. What's more, since a high proportion ofAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not recei ...